NASDAQ:CHRS Coherus BioSciences Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Coherus BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $7.83 +0.59 (+8.15%) (As of 07/1/2022 12:00 AM ET) Add Compare Share Today's Range$7.12▼$7.8750-Day Range$5.86▼$9.7252-Week Range$5.60▼$19.32Volume826,628 shsAverage Volume965,461 shsMarket Capitalization$606.22 millionP/E RatioN/ADividend YieldN/APrice Target$19.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Coherus BioSciences Stock Forecast (MarketRank)Analyst RatingModerate Buy2.60 Rating ScoreUpside/Downside142.7% Upside$19.00 Price TargetShort InterestBearish13.44% of Float Sold ShortDividend StrengthN/ASustainability-1.53Upright™ Environmental ScoreNews Sentiment0.74Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.77) to ($1.87) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.2.24 out of 5 starsMedical Sector330th out of 1,428 stocksBiological Products, Except Diagnostic Industry52nd out of 217 stocks 3.3 Analyst's Opinion Consensus RatingCoherus BioSciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $19.00, Coherus BioSciences has a forecasted upside of 142.7% from its current price of $7.83.Amount of Analyst CoverageCoherus BioSciences has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted13.44% of the float of Coherus BioSciences has been sold short.Short Interest Ratio / Days to CoverCoherus BioSciences has a short interest ratio ("days to cover") of 9.4.Change versus previous monthShort interest in Coherus BioSciences has recently decreased by 4.61%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldCoherus BioSciences does not currently pay a dividend.Dividend GrowthCoherus BioSciences does not have a long track record of dividend growth. Previous Next 3.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCoherus BioSciences has received a 61.53% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer", "Pegfilgrastim", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Coherus BioSciences is -1.53. Previous Next 2.6 News and Social Media Coverage News SentimentCoherus BioSciences has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Coherus BioSciences this week, compared to 2 articles on an average week.Social Mentions This WeekMarketBeat has tracked 23 reddit mentions for Coherus BioSciences this week, compared to 0 mentions on an average week.Search Interest2 people have searched for CHRS on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Coherus BioSciences insiders have not sold or bought any company stock.Percentage Held by Insiders11.91% of the stock of Coherus BioSciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions97.85% of the stock of Coherus BioSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Coherus BioSciences are expected to grow in the coming year, from ($3.77) to ($1.87) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Coherus BioSciences is -2.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Coherus BioSciences is -2.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCoherus BioSciences has a P/B Ratio of 6.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CHRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Coherus BioSciences and its competitors with MarketBeat's FREE daily newsletter. Email Address About Coherus BioSciences (NASDAQ:CHRS)Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.Read More CHRS Stock News HeadlinesJune 27, 2022 | finance.yahoo.comSwedish Orphan Biovitrum (BIOVF) Stock Jumps 5.3%: Will It Continue to Soar?June 18, 2022 | americanbankingnews.comCoherus BioSciences, Inc. (NASDAQ:CHRS) Receives $19.00 Consensus PT from AnalystsJune 14, 2022 | americanbankingnews.comCoherus BioSciences (NASDAQ:CHRS) Now Covered by UBS GroupJune 12, 2022 | americanbankingnews.comCoherus BioSciences (NASDAQ:CHRS) Hits New 52-Week Low at $6.93May 27, 2022 | seekingalpha.comCoherus: Will Its Chinese Gambit Fail?May 11, 2022 | finance.yahoo.comCoherus BioSciences Appoints Dr. Jill O’Donnell-Tormey to its Board of DirectorsMay 11, 2022 | finance.yahoo.comShareholders in Coherus BioSciences (NASDAQ:CHRS) have lost 61%, as stock drops 12% this past weekMay 10, 2022 | finance.yahoo.comCoherus BioSciences Management to Present at Upcoming Investor ConferencesMay 7, 2022 | finance.yahoo.comCoherus BioSciences (CHRS) Q1 2022 Earnings Call TranscriptMay 6, 2022 | seekingalpha.comCoherus BioSciences, Inc. (CHRS) CEO Denny Lanfear on Q1 2022 Earnings Call TranscriptMay 5, 2022 | apnews.comCoherus BioSciences Reports First Quarter 2022 ResultsMay 5, 2022 | finance.yahoo.comCoherus BioSciences Appoints Charlie Newton to Board of DirectorsMay 4, 2022 | seekingalpha.comCoherus BioSciences Q1 consensus EPS, revenue estimates downMay 2, 2022 | finance.yahoo.comFDA rejects Peninsula biotech's cancer drug — at least for nowMay 2, 2022 | reuters.comU.S. FDA declines to approve two more China-tested drugsMay 2, 2022 | finance.yahoo.comFDA Rejects Junshi - Coherus' Toripalimab For Rare Head & Neck CancerMay 2, 2022 | reuters.comU.S. FDA declines to approve third China-tested cancer therapyMay 2, 2022 | seekingalpha.comCoherus, Junshi hit by FDA rejection of cancer therapyMay 2, 2022 | finance.yahoo.comCoherus and Junshi Biosciences Receive Complete Response Letter from U.S. FDA for Toripalimab BLAMay 2, 2022 | finance.yahoo.comCoherus, Shanghai Junshi get complete response letter from the FDA for cancer therapyApril 29, 2022 | finance.yahoo.comCORRECTION - Coherus BioSciences to Report First Quarter 2022 Financial Results on May 5th, 2022April 29, 2022 | finance.yahoo.comCoherus BioSciences to Report First Quarter 2022 Financial Results on May 5th, 2022April 28, 2022 | finance.yahoo.comCoherus BioSciences (CHRS) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseApril 14, 2022 | finance.yahoo.comCoherus and Junshi Biosciences Announce PD-1 Inhibitor Toripalimab Granted Orphan Drug Designation for Small Cell Lung Cancer in the United StatesApril 9, 2022 | tmcnet.comJunshi Biosciences and Coherus Present Results of PhaseSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CHRS CUSIPN/A CIK1512762 Webwww.coherus.com Phone(650) 649-3530FaxN/AEmployees332Year Founded2010Company Calendar Last Earnings5/05/2022Today7/02/2022Next Earnings (Estimated)8/04/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$19.00 High Stock Price Forecast$30.00 Low Stock Price Forecast$7.00 Forecasted Upside/Downside+142.7%Consensus RatingModerate Buy Rating Score (0-4)2.6 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.730010) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-287.10 million Net Margins-69.24% Pretax Margin-69.24% Return on Equity-211.68% Return on Assets-30.54% Debt Debt-to-Equity Ratio33.47 Current Ratio3.33 Quick Ratio3.09 Sales & Book Value Annual Sales$326.55 million Price / Sales1.86 Cash FlowN/A Price / Cash FlowN/A Book Value$1.27 per share Price / Book6.17Miscellaneous Outstanding Shares77,423,000Free Float68,202,000Market Cap$606.22 million OptionableOptionable Beta1.22 Social Links Coherus BioSciences Frequently Asked Questions Should I buy or sell Coherus BioSciences stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Coherus BioSciences in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" Coherus BioSciences stock. View analyst ratings for Coherus BioSciences or view top-rated stocks. What is Coherus BioSciences' stock price forecast for 2022? 5 equities research analysts have issued 12 month price targets for Coherus BioSciences' stock. Their CHRS stock forecasts range from $7.00 to $30.00. On average, they anticipate Coherus BioSciences' share price to reach $19.00 in the next twelve months. This suggests a possible upside of 142.7% from the stock's current price. View analysts' price targets for Coherus BioSciences or view top-rated stocks among Wall Street analysts. How has Coherus BioSciences' stock performed in 2022? Coherus BioSciences' stock was trading at $15.96 on January 1st, 2022. Since then, CHRS stock has decreased by 50.9% and is now trading at $7.83. View the best growth stocks for 2022 here. When is Coherus BioSciences' next earnings date? Coherus BioSciences is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for Coherus BioSciences. How were Coherus BioSciences' earnings last quarter? Coherus BioSciences, Inc. (NASDAQ:CHRS) issued its earnings results on Thursday, May, 5th. The biotechnology company reported ($1.24) EPS for the quarter, missing the consensus estimate of ($0.80) by $0.44. The biotechnology company had revenue of $60.12 million for the quarter, compared to the consensus estimate of $68.07 million. Coherus BioSciences had a negative trailing twelve-month return on equity of 211.68% and a negative net margin of 69.24%. View Coherus BioSciences' earnings history. Who are Coherus BioSciences' key executives? Coherus BioSciences' management team includes the following people: Mr. Dennis M. Lanfear, Chairman, Pres & CEO (Age 67, Pay $1.86M) (LinkedIn Profile)Mr. McDavid Stilwell, Chief Financial Officer (Age 50, Pay $756k) (LinkedIn Profile)Mr. Vladimir Vexler Ph.D., Chief Scientific Officer (Age 64, Pay $778.28k) (LinkedIn Profile)Mr. Richard L. Hameister, Chief Technical OfficerMr. Thomas F. Fitzpatrick, Chief Legal OfficerCheston Turbyfill, VP of CommunicationsMr. Chris Thompson, Exec. VP of SalesMs. Rebecca Sunshine, Exec. VP of HR (Age 59)Mr. Michael A. Fleming, Chief Strategy OfficerMr. Michael Chen, Sr. VP of Commercial Analytics & Trade What is Dennis M. Lanfear's approval rating as Coherus BioSciences' CEO? 21 employees have rated Coherus BioSciences CEO Dennis M. Lanfear on Glassdoor.com. Dennis M. Lanfear has an approval rating of 95% among Coherus BioSciences' employees. This puts Dennis M. Lanfear in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. Who are some of Coherus BioSciences' key competitors? Some companies that are related to Coherus BioSciences include Twist Bioscience (TWST), BioCryst Pharmaceuticals (BCRX), Relay Therapeutics (RLAY), Iovance Biotherapeutics (IOVA), Krystal Biotech (KRYS), Allogene Therapeutics (ALLO), Immunocore (IMCR), ImmunityBio (IBRX), Revolution Medicines (RVMD), Recursion Pharmaceuticals (RXRX), Exscientia (EXAI), SpringWorks Therapeutics (SWTX), Vaxcyte (PCVX), Sana Biotechnology (SANA) and Vericel (VCEL). View all of CHRS's competitors. What other stocks do shareholders of Coherus BioSciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Coherus BioSciences investors own include Halozyme Therapeutics (HALO), Chembio Diagnostics (CEMI), Exelixis (EXEL), Heron Therapeutics (HRTX), TG Therapeutics (TGTX), Intelsat (I), Idera Pharmaceuticals (IDRA), Immunomedics (IMMU), Sangamo Therapeutics (SGMO) and Viking Therapeutics (VKTX). What is Coherus BioSciences' stock symbol? Coherus BioSciences trades on the NASDAQ under the ticker symbol "CHRS." How do I buy shares of Coherus BioSciences? Shares of CHRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Coherus BioSciences' stock price today? One share of CHRS stock can currently be purchased for approximately $7.83. How much money does Coherus BioSciences make? Coherus BioSciences (NASDAQ:CHRS) has a market capitalization of $606.22 million and generates $326.55 million in revenue each year. The biotechnology company earns $-287.10 million in net income (profit) each year or ($2.730010) on an earnings per share basis. How many employees does Coherus BioSciences have? Coherus BioSciences employs 332 workers across the globe. Does Coherus BioSciences have any subsidiaries? The following companies are subsidiares of Coherus BioSciences: Coherus Intermediate Corp, InteKrin, InteKrin Russia, and InteKrin Therapeutics Inc..Read More When was Coherus BioSciences founded? Coherus BioSciences was founded in 2010. How can I contact Coherus BioSciences? Coherus BioSciences' mailing address is 333 TWIN DOLPHIN DRIVE SUITE 600, REDWOOD CITY CA, 94065. The official website for Coherus BioSciences is www.coherus.com. The biotechnology company can be reached via phone at (650) 649-3530 or via email at darrington@coherus.com. This page (NASDAQ:CHRS) was last updated on 7/3/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here